Inovio Pharmaceuticals Faces Class Action Over INO-3107 Misleading Statements and Legal Challenges

Inovio Pharmaceuticals Faces Class Action Over Misleading Statements Regarding INO-3107

Inovio Pharmaceuticals, Inc. is reportedly under scrutiny following the announcement of potential class action lawsuits connected to the company’s handling of its CELLECTRA device and the associated regulatory process for its lead product, INO-3107. Plaintiffs allege that for a significant period—spanning from October 10, 2023 to December 26, 2025—Inovio failed to disclose critical manufacturing deficiencies related to its CELLECTRA device, casting doubts on the company’s ability to submit its Biologics License Application (BLA) to the FDA in the anticipated timeline. Legal experts believe that such omissions could constitute securities fraud, misleading investors regarding the actual regulatory standing and commercial potential of INO-3107.

Reports indicate that Inovio had characterized its prospects for INO-3107 optimistically, despite lacking sufficient data to support claims for accelerated approval or priority review from the FDA. The delayed acceptance of the BLA for standard review instead of expedited options reflects a serious shortfall in the company’s communications with shareholders. Allegedly, statements suggesting a positive outlook on INO-3107 have been challenged for being materially misleading, inflating expectations and contributing to investor losses when adverse information was finally disclosed. This breach of trust has led legal firms to encourage affected shareholders to participate as lead plaintiffs in the upcoming class action, with the deadline for joining set for April 7, 2026.

The ramifications of this situation extend into the broader implications for corporate accountability and transparency within the pharmaceutical sector, particularly concerning the regulatory pathways essential for drug approval. Inovio now faces ongoing legal challenges while needing to restore confidence among investors and the public. The presence of multiple law firms, including Rosen Law Firm and Levi & Korsinsky, signaling their commitment to represent potentially aggrieved shareholders, highlights the severity of the allegations against Inovio and the urgency felt by investors seeking recourse for their financial losses.

Aside from the ongoing legal challenges, Inovio Pharmaceuticals has also announced a collaboration with Akeso, Inc. to evaluate the cancer treatment potential of their combined therapies in a Phase 2 trial for glioblastoma. This partnership indicates the firm’s dedication to advancing innovative cancer treatments, even as it grapples with its legal issues surrounding INO-3107.

Investor interest remains piqued as the firm navigates its troubled waters while engaging in meaningful partnerships to enhance its pipeline. The forthcoming months will be critical for Inovio, both in addressing investor grievances and in progressing its developmental commitments in oncology.